1
|
Mohammad SA, Toragall VB, Fortenberry A, Shofolawe-Bakare O, Sulochana S, Heath K, Owolabi I, Tassin G, Flynt AS, Smith AE, Werfel T. Postpolymerization Modification of Poly(2-vinyl-4,4-dimethyl azlactone) as a Versatile Strategy for Drug Conjugation and Stimuli-Responsive Release. Biomacromolecules 2024; 25:2621-2634. [PMID: 38457653 PMCID: PMC11194783 DOI: 10.1021/acs.biomac.4c00181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/10/2024]
Abstract
Postpolymerization modification of highly defined "scaffold" polymers is a promising approach for overcoming the existing limitations of controlled radical polymerization such as batch-to-batch inconsistencies, accessibility to different monomers, and compatibility with harsh synthesis conditions. Using multiple physicochemical characterization techniques, we demonstrate that poly(2-vinyl-4,4-dimethyl azlactone) (PVDMA) scaffolds can be efficiently modified with a coumarin derivative, doxorubicin, and camptothecin small molecule drugs. Subsequently, we show that coumarin-modified PVDMA has a high cellular biocompatibility and that coumarin derivatives are liberated from the polymer in the intracellular environment for cytosolic accumulation. In addition, we report the pharmacokinetics, biodistribution, and antitumor efficacy of a PVDMA-based polymer for the first time, demonstrating unique accumulation patterns based on the administration route (i.e., intravenous vs oral), efficient tumor uptake, and tumor growth inhibition in 4T1 orthotopic triple negative breast cancer (TNBC) xenografts. This work establishes the utility of PVDMA as a versatile chemical platform for producing polymer-drug conjugates with a tunable, stimuli-responsive delivery.
Collapse
Affiliation(s)
- Sk Arif Mohammad
- Department of Biomedical Engineering, University of Mississippi, University, MS, 38677, USA
| | - Veeresh B. Toragall
- Department of Biomedical Engineering, University of Mississippi, University, MS, 38677, USA
| | - Alex Fortenberry
- Department of Chemical Engineering, University of Mississippi, University, MS, 38677, USA
| | | | - Suresh Sulochana
- Center of Biomedical Research Excellence in Natural Products Neuroscience, University of Mississippi, University, MS, 38677, USA
| | - Katie Heath
- Center of Biomedical Research Excellence in Natural Products Neuroscience, University of Mississippi, University, MS, 38677, USA
| | - Iyanuoluwani Owolabi
- Center for Molecular and Cellular Biosciences, University of Southern Mississippi, Hattiesburg, MS, 39406, USA
| | - Garrett Tassin
- Center for Molecular and Cellular Biosciences, University of Southern Mississippi, Hattiesburg, MS, 39406, USA
| | - Alex S. Flynt
- Center for Molecular and Cellular Biosciences, University of Southern Mississippi, Hattiesburg, MS, 39406, USA
| | - Adam E. Smith
- Department of Biomedical Engineering, University of Mississippi, University, MS, 38677, USA
- Department of Chemical Engineering, University of Mississippi, University, MS, 38677, USA
| | - Thomas Werfel
- Department of Biomedical Engineering, University of Mississippi, University, MS, 38677, USA
- Department of Chemical Engineering, University of Mississippi, University, MS, 38677, USA
- Department of BioMolecular Sciences, University of Mississippi, University, MS, 38677, USA
- Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson, MS, 39216, USA
| |
Collapse
|
2
|
Tang S, Shen Q, He P, Li J, Yang J, Si X, Xia J, Han Y, Li Z, Liu C, Gui QW. Synthesis of esters from 2-phenylimidazo[1,2-a]pyridines using visible light. Tetrahedron 2022. [DOI: 10.1016/j.tet.2022.133140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
3
|
pH-sensitive polymeric nanocarriers for antitumor biotherapeutic molecules targeting delivery. Biodes Manuf 2021. [DOI: 10.1007/s42242-020-00105-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Banskota S, Saha S, Bhattacharya J, Kirmani N, Yousefpour P, Dzuricky M, Zakharov N, Li X, Spasojevic I, Young K, Chilkoti A. Genetically Encoded Stealth Nanoparticles of a Zwitterionic Polypeptide-Paclitaxel Conjugate Have a Wider Therapeutic Window than Abraxane in Multiple Tumor Models. NANO LETTERS 2020; 20:2396-2409. [PMID: 32125864 DOI: 10.1021/acs.nanolett.9b05094] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Small-molecule therapeutics demonstrate suboptimal pharmacokinetics and bioavailability due to their hydrophobicity and size. One way to overcome these limitations-and improve their efficacy-is to use "stealth" macromolecular carriers that evade uptake by the reticuloendothelial system. Although unstructured polypeptides are of increasing interest as macromolecular drug carriers, current recombinant polypeptides in the clinical pipeline typically lack stealth properties. We address this challenge by developing new unstructured polypeptides, called zwitterionic polypeptides (ZIPPs), that exhibit "stealth" behavior in vivo. We show that conjugating paclitaxel to a ZIPP imparts amphiphilicity to the polypeptide chain that is sufficient to drive its self-assembly into micelles. This in turn increases the half-life of paclitaxel by 17-fold compared to free paclitaxel, and by 1.6-fold compared to the nonstealth control, i.e., ELP-paclitaxel. Treatment of mice bearing highly aggressive prostate or colon cancer with a single dose of ZIPP-paclitaxel nanoparticles leads to near-complete eradication of the tumor, and these nanoparticles have a wider therapeutic window than Abraxane, an FDA-approved taxane nanoformulation.
Collapse
Affiliation(s)
- Samagya Banskota
- Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States
| | - Soumen Saha
- Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States
| | - Jayanta Bhattacharya
- Center for Biomedical Engineering, Indian Institute of Technology Delhi, Hauz Khas, New Delhi 110016, India
| | - Nadia Kirmani
- Department of Biology, Trinity College of Arts and Sciences, Duke University, Durham, North Carolina 27708, United States
| | - Parisa Yousefpour
- Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States
| | - Michael Dzuricky
- Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States
| | - Nikita Zakharov
- Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States
| | - Xinghai Li
- Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States
| | - Ivan Spasojevic
- Department of Medicine, Pharmaceutical Research PK/PD Core Laboratory, Duke University Medical Center, Durham, North Carolina 27710, United States
| | - Kenneth Young
- Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, United States
| | - Ashutosh Chilkoti
- Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States
| |
Collapse
|
5
|
Ray P, Ferraro M, Haag R, Quadir M. Dendritic Polyglycerol-Derived Nano-Architectures as Delivery Platforms of Gemcitabine for Pancreatic Cancer. Macromol Biosci 2019; 19:e1900073. [PMID: 31183964 DOI: 10.1002/mabi.201900073] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Revised: 05/07/2019] [Indexed: 12/14/2022]
Abstract
Dendritic polyglycerol-co-polycaprolactone (PG-co-PCL)-derived block copolymers are synthesized and explored as nanoscale drug delivery platforms for a chemotherapeutic agent, gemcitabine (GEM), which is the cornerstone of therapy for pancreatic ductal adenocarcinoma (PDAC). Current treatment strategies with GEM result in suboptimal therapeutic outcome owing to microenvironmental resistance and rapid metabolic degradation of GEM. To address these challenges, physicochemical and cell-biological properties of both covalently conjugated and non-covalently stabilized variants of GEM-containing PG-co-PCL architectures have been evaluated. Self-assembly behavior, drug loading and release capacity, cytotoxicity, and cellular uptake properties of these constructs in monolayer and in spheroid cultures of PDAC cells are investigated. To realize the covalently conjugated carrier systems, GEM, in conjunction with a tertiary amine, is attached to the polycarbonate block grafted from the PG-co-PCL core. It is observed that pH-dependent ionization properties of these amine side-chains direct the formation of self-assembly of block copolymers in the form of nanoparticles. For non-covalent encapsulation, a facile "solvent-shifting" technique is adopted. Fabrication techniques are found to control colloidal and cellular properties of GEM-loaded nanoconstructs. The feasibility and potential of these newly developed architectures for designing carrier systems for GEM to achieve augmented prognosis for pancreatic cancer are reported.
Collapse
Affiliation(s)
- Priyanka Ray
- Department of Coatings and Polymeric Materials, 1735 Research Park Drive, Fargo, ND, 58108-6050, USA
| | - Magda Ferraro
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustr. 3, 14195, Berlin, Germany
| | - Rainer Haag
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustr. 3, 14195, Berlin, Germany
| | - Mohiuddin Quadir
- Department of Coatings and Polymeric Materials, 1735 Research Park Drive, Fargo, ND, 58108-6050, USA
| |
Collapse
|
6
|
Ekladious I, Liu R, Zhang H, Foil DH, Todd DA, Graf TN, Padera RF, Oberlies NH, Colson YL, Grinstaff MW. Synthesis of poly(1,2-glycerol carbonate)-paclitaxel conjugates and their utility as a single high-dose replacement for multi-dose treatment regimens in peritoneal cancer. Chem Sci 2017; 8:8443-8450. [PMID: 29619192 PMCID: PMC5863611 DOI: 10.1039/c7sc03501b] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Accepted: 10/18/2017] [Indexed: 12/13/2022] Open
Abstract
A high drug-density, biodegradable polymeric nanocarrier replaces multi-dose paclitaxel treatment regimens.
Current chemotherapeutic dosing strategies are limited by the toxicity of anticancer agents and therefore rely on multiple low-dose administrations. As an alternative, we describe a novel sustained-release, biodegradable polymeric nanocarrier as a single administration replacement of multi-dose paclitaxel (PTX) treatment regimens. The first synthesis of poly(1,2-glycerol carbonate)-graft-succinic acid-paclitaxel (PGC–PTX) is described, and its use enables high, controlled PTX loadings of up to 74 wt%. Moreover, the polymer backbone is composed of biocompatible building blocks—glycerol and carbon dioxide. When formulated as nanoparticles (NPs), PGC–PTX NPs exhibit PTX concentrations >15 mg mL–1, sub-100 nm diameters, narrow dispersity, storage stability for up to 6 months, and sustained and controlled PTX release kinetics over an extended period of 70 days. A safely administered single dose of PGC–PTX NPs contains more PTX than the median lethal dose of standard PTX. In murine models of peritoneal carcinomatosis, in which the clinical implementation of multi-dose intraperitoneal (IP) treatment regimens is limited by catheter-related complications, PGC–PTX NPs exhibit improved safety at high doses, tumor localization, and efficacy even after a single IP injection, with comparable curative effect to PTX administered as a multi-dose IP treatment regimen.
Collapse
Affiliation(s)
- Iriny Ekladious
- Departments of Biomedical Engineering and Chemistry , Boston University , Boston , MA 02215 , USA .
| | - Rong Liu
- Department of Surgery , Brigham and Women's Hospital , Boston , MA 02215 , USA .
| | - Heng Zhang
- Departments of Biomedical Engineering and Chemistry , Boston University , Boston , MA 02215 , USA .
| | - Daniel H Foil
- Department of Chemistry and Biochemistry , University of North Carolina at Greensboro , Greensboro , NC 27402 , USA
| | - Daniel A Todd
- Department of Chemistry and Biochemistry , University of North Carolina at Greensboro , Greensboro , NC 27402 , USA
| | - Tyler N Graf
- Department of Chemistry and Biochemistry , University of North Carolina at Greensboro , Greensboro , NC 27402 , USA
| | - Robert F Padera
- Department of Pathology , Brigham and Women's Hospital , Boston , MA 02215 , USA
| | - Nicholas H Oberlies
- Department of Chemistry and Biochemistry , University of North Carolina at Greensboro , Greensboro , NC 27402 , USA
| | - Yolonda L Colson
- Department of Surgery , Brigham and Women's Hospital , Boston , MA 02215 , USA .
| | - Mark W Grinstaff
- Departments of Biomedical Engineering and Chemistry , Boston University , Boston , MA 02215 , USA .
| |
Collapse
|
7
|
Bhattacharyya J, Ren XR, Mook RA, Wang J, Spasojevic I, Premont RT, Li X, Chilkoti A, Chen W. Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth. NANOSCALE 2017; 9:12709-12717. [PMID: 28828438 PMCID: PMC5863494 DOI: 10.1039/c7nr01973d] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Abnormal Wnt activity is a major mechanism responsible for many diseases, including cancer. Previously, we reported that the anthelmintic drug Niclosamide (NIC) inhibits Wnt/β-catenin signaling and suppresses colon cancer cell growth. Although the pharmacokinetic properties of NIC are appropriate for use as an anthelmintic agent, its low solubility, low bioavailability and low systemic exposure limit its usefulness in treating systemic diseases. To overcome these limitations, we conjugated NIC to recombinant chimeric polypeptides (CPs), and the CP-NIC conjugate spontaneously self-assembled into sub-100 nm near-monodisperse nanoparticles. CP-NIC nanoparticles delivered intravenously act as a pro-drug of NIC to dramatically increase exposure of NIC compared to dosing with free NIC. CP-NIC improved anti-tumor activity compared to NIC in a xenograft model of human colon cancer. Because NIC has multiple biological activities, CP-NIC could be used for treatment of multiple diseases, including cancer, bacterial and viral infection, type II diabetes, NASH and NAFLD.
Collapse
Affiliation(s)
- Jayanta Bhattacharyya
- Department of Biomedical Engineering, Duke University, Durham, NC 27708, United States
| | - Xiu-Rong Ren
- Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States
| | - Robert A. Mook
- Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States
| | - Jiangbo Wang
- Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States
| | - Ivan Spasojevic
- Duke Cancer Institute, PK/PD Core Laboratory, Durham, NC 27710, United States
| | - Richard T. Premont
- Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States
| | - Xinghai Li
- Department of Biomedical Engineering, Duke University, Durham, NC 27708, United States
| | - Ashutosh Chilkoti
- Department of Biomedical Engineering, Duke University, Durham, NC 27708, United States
| | - Wei Chen
- Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States
| |
Collapse
|
8
|
Shi B, Du X, Chen J, Fu L, Morsch M, Lee A, Liu Y, Cole N, Chung R. Multifunctional Hybrid Nanoparticles for Traceable Drug Delivery and Intracellular Microenvironment-Controlled Multistage Drug-Release in Neurons. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2017; 13:1603966. [PMID: 28371073 DOI: 10.1002/smll.201603966] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/27/2016] [Revised: 02/21/2017] [Indexed: 05/27/2023]
Abstract
Innovative nanoparticles hold promising potential for disease therapy as drug delivery systems. For brain-disease therapy, a drug delivery system that can sustainably control drug-release and monitor fluorescence of the drug cargos is highly desirable. In this study, a light-traceable and intracellular microenvironment-responsive drug delivery system was developed based on the combination of glutathione-responsive autoflurescent nanogel, dendrimer-like mesoporous silica nanoparticles, and gold nanoparticles. The resulting hybrid nanoparticles represent a new class of delivery system that can efficiently load, transport, and control multistage-release of sulfydryl-containing drugs into neurons, with light-traceable monitoring for future brain-disease therapy.
Collapse
Affiliation(s)
- Bingyang Shi
- College of Life Sciences, Henan University, Jin Ming Avenue, Kaifeng, Henan, 475004, China
| | - Xin Du
- Department of Chemistry & Biological Engineering, University of Science & Technology Beijing, Beijing, 100083, P. R. China
| | - Jian Chen
- College of Life Sciences, Henan University, Jin Ming Avenue, Kaifeng, Henan, 475004, China
| | - Libing Fu
- Faculty of Medicine & Health Sciences, Macquarie University, Sydney, NSW, 2109, Australia
| | - Marco Morsch
- Faculty of Medicine & Health Sciences, Macquarie University, Sydney, NSW, 2109, Australia
| | - Albert Lee
- Faculty of Medicine & Health Sciences, Macquarie University, Sydney, NSW, 2109, Australia
| | - Yong Liu
- Institute of Advanced Materials for Nano-Bio Applications, Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China
| | - Nicholas Cole
- Faculty of Medicine & Health Sciences, Macquarie University, Sydney, NSW, 2109, Australia
| | - Roger Chung
- Faculty of Medicine & Health Sciences, Macquarie University, Sydney, NSW, 2109, Australia
| |
Collapse
|